There is an opinion which points out the need to review legitimacy of multinational pharmaceutical companies in supporting domestic clinical trials

'Illegal kickback Two-strike out system' is just around the corner, and some within pharmaceutical manufacturers society are voicing an opinion which points out need to review the overall domestic activities of multinational pharmaceutical companies.

They are insisting that inspection is needed to screen whether clinical research-related expenses which multinational pharmaceutical companies su...